BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 1845132)

  • 21. In vitro and in vivo activity of human recombinant granulocyte-macrophage colony-stimulating factor in dogs.
    Mayer P; Werner FJ; Lam C; Besemer J
    Exp Hematol; 1990 Oct; 18(9):1026-33. PubMed ID: 2168838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW; Bernstein SH
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
    Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
    Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose non-glycosylated rhGM-CSF is effective for the treatment of delayed hematopoietic recovery after autologous marrow or peripheral blood stem cell transplantation.
    Ippoliti C; Przepiorka D; Giralt S; Andersson BS; Wallerstein RO; Gutterman J; Deisseroth AB; Champlin RE
    Bone Marrow Transplant; 1993 Jan; 11(1):55-9. PubMed ID: 8094309
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of intravenously administered bacterially synthesized granulocyte-macrophage colony-stimulating factor and comparison with subcutaneous administration.
    Lieschke GJ; Maher D; O'Connor M; Green M; Sheridan W; Rallings M; Bonnem E; Burgess AW; McGrath K; Fox RM
    Cancer Res; 1990 Feb; 50(3):606-14. PubMed ID: 2404573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
    Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
    Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of CSFs in preleukemia.
    Greenberg PL; Negrin R; Nagler A
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():121-6. PubMed ID: 1697191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor.
    Lemoli RM; Fogli M; Fortuna A; Motta MR; Rizzi S; Benini C; Tura S
    Exp Hematol; 1993 Dec; 21(13):1668-72. PubMed ID: 7694867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The combined effects of interleukin-11, stem cell factor, and granulocyte colony-stimulating factor on newborn rat hematopoiesis: significant enhancement of the absolute neutrophil count.
    Cairo MS; Plunkett JM; Schendel P; van de Ven C
    Exp Hematol; 1994 Oct; 22(11):1118-23. PubMed ID: 7523164
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind placebo-controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma.
    de Vries EG; Biesma B; Willemse PH; Mulder NH; Stern AC; Aalders JG; Vellenga E
    Cancer Res; 1991 Jan; 51(1):116-22. PubMed ID: 1988077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts.
    Herrmann F; Lindemann A; Klein H; Lübbert M; Schulz G; Mertelsmann R
    Leukemia; 1989 May; 3(5):335-8. PubMed ID: 2654495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Current status of the clinical application of hematopoietic growth factors in oncology].
    Karthaus M; Ganser A
    Ther Umsch; 1996 Nov; 53(11):863-73. PubMed ID: 8984692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Yeast-expressed granulocyte-macrophage colony-stimulating factor in cancer patients: a phase ib clinical study.
    Herrmann F; Schulz G; Lindemann A; Meyenburg W; Oster W; Krumwieh D; Mertelsmann R
    Behring Inst Mitt; 1988 Aug; (83):107-18. PubMed ID: 2467645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mobilization of peripheral blood stem cells by subcutaneous injections of yeast-derived granulocyte macrophage colony stimulating factor: a phase I-II study.
    Mangan K; Mullaney M; Klumpp T; Goldberg S; Macdonald J
    Stem Cells; 1993 Sep; 11(5):445-54. PubMed ID: 8241955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of recombinant granulocyte colony-stimulating factor (rG-CSF) and recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF) on acute radiation hematopoietic injury in mice.
    Tanikawa S; Nakao I; Tsuneoka K; Nara N
    Exp Hematol; 1989 Sep; 17(8):883-8. PubMed ID: 2475360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group.
    Gerhartz HH; Marcus R; Delmer A; Zwierzina H; Suciu S; Dardenne M; Solbu G; de Witte T; Jacobs A; Visani G
    Leukemia; 1994 Jan; 8(1):16-23. PubMed ID: 8289481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
    Hansen B; Hippe E; Jacobsen GK; Johnsen HE
    Ugeskr Laeger; 1992 Jun; 154(24):1697-702. PubMed ID: 1378668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.